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Abstract
Background: Loss of muscle mass and function may be more pronounced in older adults with chronic kidney
disease (CKD) and with albuminuria. Thus, we investigated the prevalence of sarcopenia among community-dwelling
older adults according to kidney function and grade of albuminuria. We also explored differences in the prevalence of
sarcopenia according to three different equations for the estimation of glomerular filtration rate (eGFR).
Methods: A cross-sectional analysis of 1420 community-dwelling older adults (≥75 years old) included in the SCOPE
study, a multicenter prospective cohort study, was conducted. Comprehensive geriatric assessment including short
physical performance battery (SPPB), handgrip strength test and bioelectrical impedance analysis (BIA) was performed.
Sarcopenia was defined using the updated criteria of the European Working Group on Sarcopenia in Older People
(EWGSOP2). eGFR was calculated using Berlin Initiative Study (BIS), Chronic Kidney Disease Epidemiological Collaboration
(CKD-EPI) and Full Age Spectrum (FAS) equations, and urinary albumin-to-creatinine ratio (ACR) was collected to
categorize CKD according to Kidney Disease Improving Global Outcomes guidelines.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: a.corsonello@inrca.it
13Laboratory of Geriatric Pharmacoepidemiology and Biostatistics, IRCCS
INRCA, Via S. Margherita 5, 60124 Ancona, Italy
14Italian National Research Center on Aging (IRCCS INRCA), Ancona, Fermo
and Cosenza, Italy
Full list of author information is available at the end of the article
Moreno-Gonzalez et al. BMC Geriatrics 2020, 20(Suppl 1):327
https://doi.org/10.1186/s12877-020-01700-x
(Continued from previous page)
Results: Median age was 79.5 years (77.0–83.0), 804 (56.6%) were women. Using EWGSOP2 definition, 150 (10.6%)
participants met diagnostic criteria for sarcopenia. Moreover, 85 (6%) participants had severe sarcopenia. Sarcopenia was
more prevalent in participants with more advanced stages of CKD according to BIS eq. (9.6% in stages 1 and 2 and 13.9%
in stages 3a, 3b and 4, p = 0.042), and also according to CKD-EPI (9.8% vs. 14.2%, p = 0.042) and FAS although not
reaching statistical signification (9.8% vs. 12.7%, p = 0.119). Thus, differences in prevalence are observed among CKD
categories as estimated by different equations. Prevalence of sarcopenia was also higher with increasing albuminuria
categories: 9.3% in normoalbuminuric, 13.2% in microalbuminuric and 16.8% in macroalbuminuric participants, (p= 0.019).
Conclusions: Sarcopenia is common among community-dwelling older adults, especially among those with more
advanced CKD categories, with prevalence estimates differing slightly depending on the equation used for the estimation
of eGFR; as well as among those with higher albuminuria categories.
Keywords: Older adults, Sarcopenia, Chronic kidney disease, Albuminuria, EWGSOP2, Estimated glomerular filtration rate
Background
The ageing process is characterised by quantitative and
qualitative changes in body composition. Those affecting
skeletal muscle mass and function are among the most
relevant [1]. Sarcopenia is a muscle disease rooted in ad-
verse muscle changes that accrue across a lifetime and is
common among older adults, while it can also occur
earlier in life. It represents a major cause of falls, is asso-
ciated with other adverse health outcomes and predicts
disability and mortality in older people [2]. Many defini-
tions of sarcopenia have been proposed, even through
various consensus from several societies such as the
European Society of Clinical Nutrition (ESPEN) [3],
European Working Group on Sarcopenia in Older
People (EWGSOP) [4], International Working Group on
Sarcopenia (IWGS) [5], Society on Sarcopenia, Cachexia
and Wasting Disorders (SCWD) [6], Asian Working
Group for Sarcopenia (AWGS) [7] and Foundation for
the National Institutes of Health (FNIH) [8]. Differences
exist in the criteria used for an operational definition,
the tools used to measure them including different
methods to adjust for body size, and the cut-off points
used for each variable; thus leading to heterogeity in re-
search studies and clinical practice, and to differences in
prevalence estimates [9–11]. Recently, the EWGSOP up-
dated the original definition of sarcopenia (EWGSOP2)
[12], considering muscle strength as a central determin-
ant of sarcopenia, suggesting specific tools and cut-off
points for each variable defining sarcopenia, and also
proposing a clinical algorithm for the identification,
diagnosis and severity assessment of sarcopenia in a
stepwise fashion. Thus, sarcopenia is considered prob-
able when low muscle strength is detected, confirmed
when low muscle mass is also evidenced, and severe
when additionally low physical performance is present.
Chronic kidney disease (CKD) prevalence increases
with age, and is often associated with additional comor-
bid conditions. In patients with CKD, loss of muscle
mass is much more intense and the first signs of
sarcopenia are observed in younger patients than it is
expected [13]. Sarcopenia is more common among pa-
tients in the most advanced stages of CKD and is signifi-
cantly associated with glomerular filtration rate (GFR)
decline [14, 15]. Moreover, a bidirectional interaction
between sarcopenia and albuminuria has been reported,
sarcopenia is more prevalent in individuals with albu-
minuria than in those without; furthermore, increased
albuminuria is independently associated with low muscle
mass in patients with type 2 diabetes [16, 17].
The present study aimed to investigate the prevalence
of sarcopenia as derived from the recently updated
EWGSOP2 definition among a clinically relevant source
of community-dwelling older adults, and to further as-
sess its distribution according to different kidney func-
tion categories and grades of albuminuria, in the frame
of the Screening for Chronic Kidney Disease among
Older People across Europe (SCOPE) study. A second
objective was to explore possible differences between
three distinct equations for the estimation of GFR and
the prevalence of sarcopenia.
Methods
Study design and participants
This cross-sectional study used data from the SCOPE
study (European Grant Agreement no. 436849), a multi-
center 2-year prospective cohort study involving patients
older than 75 years attending geriatric and nephrology
outpatient services in participating institutions in
Austria, Germany, Israel, Italy, the Netherlands, Poland
and Spain. Methods of the SCOPE study have been ex-
tensively described elsewhere [18]. Patients were re-
quested to sign a written informed consent before
entering the study. The study protocol was approved by
ethics committees at all participating institutions, and
complies with the Declaration of Helsinki and Good
Clinical Practice Guidelines. Briefly, exclusion criteria
were: a. Age < 75 years; b. End-stage renal disease
(ESRD) (eGFR < 15ml/min/1.73 m2) or dialysis at the
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time of enrollment; c. History of solid organ or bone
marrow transplantation; d. Active malignancy within 24
months prior to screening or metastatic cancer; e. Life
expectancy less than 6 months; f. Severe cognitive im-
pairment (Mini Mental State Examination < 10); g. Any
medical or other reason (e.g. known or suspected inability
of the patient to comply with the protocol procedure) in
the judgement of the investigators, that the patient is un-
suitable for the study; h. Unwilling to provide consent and
those who cannot be followed-up. After obtaining written
informed consent, all participants underwent an extensive
baseline visit including routine laboratory analysis and
comprehensive geriatric assessment (CGA). The baseline
visit was followed by follow-up visits at 12 and 24months
with intermediate phone contacts at 6 and 18months.
Only baseline data were used in the present study.
Overall, 2461 participants were intially enrolled in the
study. Of them, 204 participants with missing serum cre-
atinine and/or urinary albumin-to-creatinine ratio (ACR)
were excluded, thus leaving a sample of 2257 partici-
pants to be included in the initial analysis. For the aim
of the present study, only those participants in whom
sarcopenia could be assessed in its three components
(i.e., muscle strength, muscle mass and physical per-
formance) were considered. Data for muscle strength, as
assessed by grip strength; muscle mass, as assessed by
bioelectrical impedance analysis (BIA); and physical per-
formance, as assessed by the Short Physical Performance
Battery (SPPB) were available for 2138 (94.7%), 1462
(64.8%) and 2256 (99.9%) participants respectively.
Participants with missing data mainly included those
physically unable or unsteady, those presenting arthral-
gia or arthritis, those with an implanted cardioverter-
defibifrillator or pacemaker, or those not assessed due to
any other safety reason in the judgement of the investi-
gators. 1420 participants were finally included, for whom
demographic and clinical characteristics were analysed.
Anthropometric measures were collected and body mass
index (BMI) was calculated as recommended in the
ESPEN guidelines [19]. Cognitive function was assessed
with the Mini Mental State Examination (MMSE) [20];
depressive symptoms were assessed with the Geriatric
Depression Scale (GDS) in its short form [21]; the ability
to perform activities of daily living (ADL) [22] and in-
strumental activities of daily living (IADL) [23] was also
assessed. The Cumulative Illness Rating Scale for geriat-
rics (CIRS-G) [24] was administered to account for co-
morbidity burden. There were no statistically significant
differences between both groups in age, gender, living
alone rate, education years, ADL score, MMSE score,
number of chronic medications and serum cretinine
levels, although higher IADL score, GDS score and
CIRS-G total score (though not higher severity index)
were observed among the excluded study participants.
Assessment of sarcopenia
Following the revised EWGSOP2 criteria for an oper-
ational definition of sarcopenia [12], all three compo-
nents, i.e. muscle strength, muscle mass, and physical
performance were assessed. Probable sarcopenia was
identified when low muscle strength was present, diag-
nosis of sarcopenia was confirmed when low muscle
strength and low muscle mass were both evidenced, and
criteria for severe sarcopenia were met when sarcopenia
concurred with low physical performance.
Muscle strength was assessed through the handgrip
strength test [25], using a hydraulic grip strength dyna-
mometer (Model J00105 JAMAR Hydraulic Hand, Lafa-
yette Instrument Company, USA). Participants were
encouraged to squeeze as hard as they could, 3 attempts
were allowed for each hand alternating sides and the
maximum measurement was registered. EWGSOP2 rec-
ommended cut-off points for low muscle strength were
used, < 27 kg for men and < 16 kg for women.
Body composition in terms of fat and fat-free mass
was assessed by BIA using the AKERN BIA 101 New
Edition 50 kHz monofrequency device (AKERN SRL,
Florence, Italy). Appendicular skeletal muscle mass
(ASM) was estimated using the Sergi et al. equation [26],
a cross-validated equation for standardisation specifically
derived from older European populations, as recom-
mended by the EWGSOP2 consensus. A decision was
made to apply no adjustment for body size to ASM mea-
sures, as also contemplated in the consensus. Following
the EWGSOP2 cut-off points, low muscle mass was de-
fined by an ASM < 20.0 kg for men and < 15 kg for
women.
Physical performance was assessed by the SPPB, a
composite test consisting of a balance test (ability to
stand for 10 s with feet close together side by side, then
in semi-tandem and then in full-tandem positions), a
gait speed assessment (usual time to walk 4 m), and a
chair stand test (time to raise from a chair and return to
the seated position 5 times without using arms) [27]. A
score from 0 to 4 was assigned to each test, thus sum-
ming up to a maximum total score of 12. As suggested
by the EWGSOP2 consensus, a total score of ≤8 was
considered to indicate low physical performance.
Assessment of kidney function
Serum creatinine was measured at local level by stand-
ard methods. Creatinine-based eGFR was calculated
using the following equations:
Berlin Initiative Study (BIS) [28]:
3736 x creatinine‐0:87x age‐0:95x 0:82 if femaleð Þ
Chronic Kidney Disease Epidemiological Collaboration
(CKD-EPI) [29]:
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Female
Scr≤0:7ð Þ eGFR ¼ 144 x Scr=0:7ð Þ‐0:329x 0:993ð ÞAge
Scr > 0:7ð Þ eGFR ¼ 144 x Scr=0:7ð Þ‐1:209x 0:993ð ÞAge
Male
Scr≤0:9ð Þ eGFR ¼ 141 x Scr=0:9ð Þ‐0:411x 0:993ð ÞAge
Scr > 0:9ð Þ eGFR ¼ 141 x Scr=0:9ð Þ‐1:209x 0:993ð ÞAge
Full Age Spectrum (FAS) [30]:
107:3= creatinine=Qð Þ½  x 0:988 Age‐40ð Þfor age
> 40 years
Q =median Scr value for age−/sex-specific healthy
populations.
Categories of CKD were defined according to Kidney
Disease Improving Global Outcomes (KDIGO) guide-
lines [31], moreover CKD categories were we further
combined into two groups, i.e., eGFR ≥60ml/min/1.73
m2 (categories 1 and 2) and eGFR < 60ml/min/1.73 m2
(categories 3a, 3b and 4). Albumin in urine was detected
by urine spot analysis and expressed as mg albumin per
gram urine (mg/g), and albumin-to-creatinine ratio
(ACR) was calculated and reported as mg albumin per
gram creatinine (mg/g). Categories of albuminuria were
also defined according to KDIGO guidelines, thus, nor-
moalbuminuria was defined as ACR < 30mg/g, microal-
buminuria as ACR 30–300mg/g and macroalbuminuria
as ACR > 300mg/g.
Statistical analysis
All variables were checked for normality by the
Kolmogorov–Smirnov test. Continuous and normally
variables are expressed as mean and standard deviation.
Non-normally distributed variables are expressed as me-
dian and interquartile difference. Categorical variables are
expressed as number and percentage.
The association between categorical variables was
analyzed by the Chi-square test, with the correction of
continuity when indicated. The relation between quanti-
tative variables, according to sarcopenia categories, was
performed by ANOVA test. Statistical significance was
set at p < 0.05. All statistical analyses were performed
with SPSS version 24 (SPSS Inc., Chicago, IL, USA) and
MedCalc (JMP® statistics software, USA).
Results
General characteristics of the 1420 participants evalu-
ated are presented in Table 1. Median age was 79.5 years
(77.0–83.0), there were 804 (56.6%) women and 337 par-
ticipants (23.7%) were living alone. Regarding daily life
activities, median ADL score was 0.0 (0.0–1.0), and 55
participants (3.9%) were considered as dependent; me-
dian IADL score was 2.0 (0.0–8.0), and 590 participants
(41.5%) were considered as dependent. With respect to
cognition, median MMSE score was 29.0 (27.0–30.0),
with 104 participants (7.3%) showing MMSE scores < 24.
Regarding depressive symptoms, median GDS score was
2.0 (1.0–4.0), and 170 participants (12%) exhibited scores
of 5 and higher. The median CIRS-G comorbitidy total
score was 7.0 (5.0–11.0), while median CIRS-G severity
index was 1.5 (1.2–1.8). The median number of current
medications was 6.0 (4.0–9.0).
Median BMI was 27.0 kg/m2 (24.4–30.0) and accord-
ing to a BMI cut-off value of ≥30 kg/m2, 359 participants
(25.3%) were obese, 143 men (23.2%) and 216 women
(26.9%); whereas according to fat mass percentage
(FM%) cut-off values of ≥25% for men and ≥ 35% for
women, 768 participants (54.1%) were obese, 355 men
(57.6%) and 413 women (51.4%), median FM% was 31.0
(24.9–37.1).
Kidney function and albuminuria
The median serum creatinine concentration was 0.93
mg/dl (0.78–1.21) (Table 1). Median eGFR values (ml/
min/1.73 m2) according to three different equations were
56.4 (45.8–64.8) (BIS), 68.4 (52.6–80.7) (CKD-EPI) and
56.8 (44.7–66.5) (FAS). Distribution of participants
among eGFR categories and according to the different
equations is presented in Table 1. When considered to-
gether, 873 participants (61.5%) according to BIS, 494
(34.8%) according to CKD-EPI, and 841 (59.2%) accord-
ing to FAS had stage 3a, 3b or 4 CKD (eGFR < 60ml/
min/1.73 m2). The median ACR value was 12.6 mg/g
(4.7–32.8), and 1037 participants (73%) had normoalbu-
minuria, 288 (20.3%) had microalbuminuria and 95
(6.7%) had macroalbuminuria.
Sarcopenia components and categories (Table 2)
Median grip strength was 24.0 kg (18.0–31.0), and 306
(21.5%) participants showed low muscle strength accord-
ing to the aforementioned cut-off values, 136 men
(22.1%) and 170 women (21.1%) (p = 0.672). Median
ASM as derived from BIA was 18.1 kg (15.2–21.7), and
following the EWGSOP2 recommended cut-off values,
463 participants (32.6%) exhibited low muscle mass, with
a statistically significant female predominance: 312
women (38.8%) vs. 151 men (24.5%) (p < 0.001). Regard-
ing SPPB, median score was 10.0 (8.0–11.0), and consid-
ering the recommended cut-off value of ≤8 points, 440
participants (31%) had low physical performance, a con-
dition also exhibited more often by female participants
(p = 0.003): 275 women (34.2%) vs. 165 men (26.8%).
Nearly half of the study sample (599 participants,
42.2%) showed no derangement in either muscle
strength, muscle mass or physical performance, a condi-
tion observed in 303 men (49.2%) and 296 women
(26.8%). Prevalence of sarcopenia in the present study
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was 10.6%, with a total of 150 participants meeting cri-
teria for sarcopenia, 59 men (9.6%) and 91 women
(11.3%) (p = 0.29). Among the non-sarcopenic partici-
pants, 1114 (78.5% of the study sample) had normal
muscle strength, 480 men (77.9%) and 634 women
(78.9%); and 156 participants (11%) had low muscle
strength, 77 men (12.5%) and 79 women (9.8%). Among
the sarcopenic participants, 65 (4.6% of the study sam-
ple) had normal physical performance, 26 men (4.2%)
and 39 women (4.9%); and 85 participants (6%) had low
physical performance, 33 men (5.4%) and 52 women
(6.5%), therefore meeting criteria for severe sarcopenia.
Differences in rates of sarcopenia categories between
men and women showed no statistical significance.
Sarcopenia according to kidney function (Tables 3, 4, 5 and 6)
According to BIS (Table 3), sarcopenia was significantly
more prevalent in the more advanced stages of CKD: 9.6%
in stages 1 and 2 (eGFR ≥60ml/min/1.73m2) vs. 13.9% in
stages 3a, 3b and 4 (eGFR < 60ml/min/1.73m2) (p =
0.024). Similarly, rates of severe sarcopenia were also
higher in participants in CKD stages 3–4 than in CKD
stages 1–2 (4.7% vs. 10.3%), with statistical significance
(p = 0.005), and were highest in CKD stage 4 (13.9%).
Table 1 General characteristics of the study population
N = 1420
Age, years 79.5 (77.0–83.0)
Women 804 (56.6%)
Living alone 337 (23.7%)
Education, years 11.0 (8.0–14.0)
ADL score 0.0 (0.0–1.0)
ADL dependent 55 (3.9%)
IADL score 2.0 (0.0–8.0)
IADL dependent 590 (41.5%)
MMSE score 29.0 (27.0–30.0)
MMSE < 24 104 (7.3%)
GDS score 2.0 (1.0–4.0)
GDS > 5 170 (12.0%)
CIRS-G total score 7.0 (5.0–11.0)
CIRS-G severity index 1.5 (1.2–1.8)
Number of current medications 6.0 (4.0–9.0)
Creatinine, mg/dl 0.93 (0.78–1.21)
BIS eGFR, ml/min/1.73 m2 56.4 (45.8–64.8)
≥ 90 9 (0.6%)
60–89 538 (37.9%)
45–59 542 (38.2%)
30–44 259 (18.2%)
15–29 72 (5.1%)
≥ 60 547 (38.5%)
< 60 873 (61.5%)
CKD-EPI eGFR, ml/min/1.73 m2 68.4 (52.6–80.7)
≥ 90 42 (3.0%)
60–89 884 (62.3%)
45–59 247 (17.4%)
30–44 163 (11.5%)
15–29 84 (5.9%)
≥ 60 926 (65.2%)
< 60 494 (34.8%)
FAS eGFR, ml/min/1.73 m2 56.8 (44.7–66.5)
≥ 90 26 (1.8%)
60–89 553 (38.9%)
45–59 480 (33.8%)
30–44 253 (17.8%)
15–29 108 (7.6%)
≥ 60 579 (40.8%)
< 60 841 (59.2%)
ACR, mg/g 12.6 (4.7–32.8)
< 30 1037 (73.0%)
30–300 288 (20.3%)
> 300 95 (6.7%)
Table 1 General characteristics of the study population
(Continued)
N = 1420
Anthropometric measurements
height, cm 162.0 (156.0–170.0)
weight, kg 72.0 (62.7–82.0)
BMI, kg/m2 27.0 (24.4–30.0)
BIA parameters
FFM, percentage 69.0 (62.9–75.0)
FFM, kg 48.5 (42.6–57.5)
FFMI, kg/m2 18.5 (17.1–20.2)
FM, percentage 31.0 (24.9–37.1)
FM, kg 21.9 (16.7–28.6)
FMI, kg/m2 8.3 (6.3–10.9)
ASM, percentage 0.25 (0.23–0.28)
ASM, kg 18.1 (15.2–21.7)
ASMI, kg/m2 6.9 (6.2–7.6)
Grip strength, kg 24.0 (18.0–31.0)
SPPB score 10.0 (8.0–11.0)
Note: continuous variables are expressed as median and interquartile
difference. Abbreviations ACR Albumin-to-creatinine ratio, ADL Activities of
daily living, ASM Appendicular skeletal muscle mass, ASMI Appendicular
skeletal muscle mass index, BIA Bioelectrical impedance analysis, BIS Berlin
Initiative Study, BMI Body mass index, CIRS-G Cumulative illness rating scale for
geriatrics, CKD-EPI Chronic Kidney Disease Epidemiological Collaboration, eGFR
Estimated glomerular filtration rate, FAS Full Age Spectrum, FFM Fat-free mass,
FFMI Fat-free mass index, FM Fat mass, FMI Fat mass index, GDS Geriatric
depression scale, IADL Instrumental activities of daily living, MMSE Mini mental
state examination, SSPB Short physical performance battery
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Sarcopenia prevalence was also higher in CKD stages
3–4 compared with CKD stages 1–2 (p = 0.042) when
eGFR was estimated using CKD-EPI equation (Table 4),
although prevalence rates differed slightly: 9.8% vs.
14.2%. Rates of severe sarcopenia were 5.2% vs. 9.7% re-
spectively, though difference was not statistically signifi-
cant (p = 0.105), with rates being lowest in CKD stage 1
(4.8%), and highest in CKD stage 4 (10.7%).
Finally, when eGFR was calculated with FAS formula
(Table 5), prevalence of sarcopenia was 9.8% (eGFR ≥60
ml/min/1.73 m2) vs. 12.7% (eGFR < 60), though differ-
ences were not statistically significant (p = 0.119). Higher
percentages of severely sarcopenic participants were ob-
served among CKD stages 3–4 (9.4%) compared with
stages 1–2 (4.8%) (p = 0.005), and were highest among
CKD stage 4 participants (13.9%).
Therefore, higher rates of sarcopenia and severe sarco-
penia were observed among participants in more
advanced stages of CKD, irrespective of the equation
used for the estimation of eGFR, although sarcopenia
prevalence varied slightly in those with eGFR < 60ml/
min/1.73m2: 13.9% with BIS, 14.2% with CKD-EPI and
12.7% with FAS equations.
Finally, the distribution of participants according to
ACR categories also yielded significantly higher preva-
lence rates of sarcopenia with increasing albuminuria
categories: 9.3% in normoalbuminuria, 13.2% in microal-
buminuria and 16.8% in macroalbuminuria (p = 0.019).
Similarly, as ACR rised, higher rates of severe sarcopenia
were observed: 4.8, 8.3 and 11.6% respectively, although
without statistical significance (p = 0.297).
Discussion
In the SCOPE study, where community-dwelling older
adults (75 years and older) from 7 European countries
within a wide range of kidney function were evaluated
Table 2 Summary of sarcopenia components and sarcopenia categories, stratified by gender
Total (n = 1420) Men (n = 616) Women (n = 804) p-value
Sarcopenia components
Low muscle strength 306 (21.5%) 136 (22.1%) 170 (21.1%) 0.672
Low muscle mass 463 (32.6%) 151 (24.5%) 312 (38.8%) < 0.001
Low physical performance 440 (31.0%) 165 (26.8%) 275 (34.2%) 0.003
Sarcopenia categories
No sarcopenia 1114 (78.5%) 480 (77.9%) 634 (78.9%) 0.672
Probable sarcopenia 156 (11.0%) 77 (12.5%) 79 (9.8%) 0.110
Confirmed sarcopenia 65 (4.6%) 26 (4.2%) 39 (4.9%) 0.573
Severe sarcopenia 85 (6.0%) 33 (5.4%) 52 (6.5%) 0.382
Table 3 Prevalence of sarcopenia and sarcopenia categories according to BIS eGFR (ml/min/1.73m2) categories
Non-sarcopenic (n = 1270) Sarcopenic (n = 150) p-value
BIS eGFR category No sarcopenia (n = 1114) Probable sarcopenia (n = 156) Confirmed sarcopenia (n = 65) Severe sarcopenia (n = 85)
≥90 (n = 9) 6 (66.7%) 3 (33.3%) 0.026
3 (33.3%) 3 (33.3%) 2 (22.2%) 1 (11.1%)
60–89 (n = 538) 483 (89.8%) 55 (10.2%) 0.745
440 (81.8%) 43 (8.0%) 26 (4.8%) 29 (5.4%)
45–59 (n = 542) 496 (91.5%) 46 (8.5%) 0.046
436 (80.4%) 60 (11.1%) 25 (4.6%) 21 (3.9%)
30–44 (n = 259) 225 (86.9%) 34 (13.1%) 0.138
188 (72.6%) 37 (14.3%) 10 (3.9%) 24 (9.3%)
15–29 (n = 72) 60 (83.3%) 12 (16.7%) 0.084
47 (65.3%) 13 (18.1%) 2 (2.8%) 10 (13.9%)
≥60 (n = 1089) 985 (90.4%) 104 (9.6%) 0.024
879 (80.7%) 106 (9.7%) 53 (4.9%) 51 (4.7%)
< 60 (n = 331) 285 (86.1%) 46 (13.9%)
235 (71.0%) 50 (15.1%) 12 (3.6%) 34 (10.3%)
BIS Berlin Initiative Study, eGFR Estimated glomerular filtration rate
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(from normal to stage 4 CKD, therefore excluding pa-
tients with ESRD); one of ten community-dwelling older
adults had sarcopenia, and 6% of the evaluated partici-
pants had severe sarcopenia. Women had higher rates of
low muscle mass and more often exhibited low physical
performance than men; and although sarcopenia was
present in 11.3% of women and 9.6% of men, and severe
sarcopenia in 6.5% of women and 5.4% of men, differences
were not statistically significant. Our study found that a
higher prevalence of sarcopenia is observed among
participants with poorer kidney function categories (CKD
stages 3–4) compared with participants with better kidney
function categories (CKD stages 1–2), irrespective of the
equation used to estimate eGFR (BIS, CKD-EPI or FAS),
with prevalence rates of 13.9, 14.2 and 12.7% respectively,
according to the EWGSOP2 revised criteria for sarcopenia
[12]. These findings are clinically relevant, especially when
considering that sarcopenia may affect mobility and in-
crease the risk of falls among older individuals. Indeed,
muscle mass and strength were formerly found to be
Table 4 Prevalence of sarcopenia and sarcopenia categories according to CKD-EPI eGFR (ml/min/1.73m2) categories
Non-sarcopenic (n = 1270) Sarcopenic (n = 150) p-value
CKD-EPI eGFR
category
No sarcopenia (n = 1114) Probable sarcopenia (n = 156) Confirmed sarcopenia (n = 65) Severe sarcopenia (n = 85)
≥90 (n = 42) 37 (88.1%) 5 (11.9%) 0.774
29 (69.0%) 8 (19.0%) 3 (7.1%) 2 (4.8%)
60–89 (n = 884) 795 (89.9%) 89 (10.1%) 0.435
720 (81.4%) 75 (8.5%) 46 (5.2%) 43 (4.9%)
45–59 (n = 247) 226 (91.5%) 21 (8.5%) 0.246
194 (78.5%) 32 (13.0%) 5 (2.0%) 16 (6.5%)
30–44 (n = 163) 139 (85.3%) 24 (14.7%) 0.066
112 (68.7%) 27 (16.6%) 9 (5.5%) 15 (9.2%)
15–29 (n = 84) 73 (86.9%) 11 (13.1%) 0.436
59 (70.2%) 14 (16.7%) 2 (2.4%) 9 (10.7%)
≥60 (n = 1173) 1058 (90.2%) 115 (9.8%) 0.042
943 (80.4%) 115 (9.8%) 54 (4.6%) 61 (5.2%)
< 60 (n = 247) 212 (85.8%) 35 (14.2%)
171 (69.2%) 41 (16.6%) 11 (4.5%) 24 (9.7%)
CKD-EPI Chronic Kidney Disease Epidemiological Collaboration, eGFR Estimated glomerular filtration rate
Table 5 Prevalence of sarcopenia and sarcopenia categories according to FAS eGFR (ml/min/1.73m2) categories
Non-sarcopenic (n = 1270) Sarcopenic (n = 150) p-value
FAS eGFR category No sarcopenia (n = 1114) Probable sarcopenia (n = 156) Confirmed sarcopenia (n = 65) Severe sarcopenia (n = 85)
≥90 (n = 26) 22 (84.6%) 4 (15.4%) 0.420
16 (61.5%) 6 (23.1%) 2 (7.7%) 2 (7.7%)
60–89 (n = 553) 496 (89.7%) 57 (10.3%) 0.802
456 (82.5%) 40 (7.2%) 29 (5.2%) 28 (5.1%)
45–59 (n = 480) 437 (91.0%) 43 (9.0%) 0.160
380 (79.2%) 57 (11.9%) 22 (4.6%) 21 (4.4%)
30–44 (n = 253) 225 (89.0%) 28 (11.1%) 0.774
188 (74.3%) 37 (14.6%) 9 (3.6%) 19 (7.5%)
15–29 (n = 108) 90 (83.3%) 18 (16.7%) 0.032
74 (68.5%) 16 (14.8%) 3 (2.8%) 15 (13.9%)
≥60 (n = 1059) 955 (90.2%) 104 (9.8%) 0.119
852 (80.5%) 103 (9.7%) 53 (5.0%) 51 (4.8%)
< 60 (n = 361) 315 (87.3%) 46 (12.7%)
262 (72.6%) 53 (14.7%) 12 (3.3%) 34 (9.4%)
eGFR Estimated glomerular filtration rate, FAS Full Age Spectrum
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linearly associated with mobility impairment [32], and the
contribution of sarcopenia to unexplained falls is still to
be elucidated [33]. Thus, our results suggest that the as-
sessment of sarcopenia may be helpful in identifying older
CKD patients at risk of falling and implementing inherent
preventive measures.
Previous studies have found differences in prevalence
estimates of sarcopenia when operational criteria pro-
posed from various existing consensus were compared
[9–11]. A recent systematic review and meta-analysis
[10] found higher prevalence rates when a single meas-
ure of muscle mass was used to define sarcopenia in-
stead of composite definitions, and that prevalence
estimates also depended on the use of BIA vs. dual-
energy X-ray absorptiometry (DXA) to assess muscle
mass, the cut-off points employed or even the method of
adjustment for body size. Recently, EWGSOP2 criteria
have been found to yield lower prevalence estimates
(9.3% overall, 11.9% in men and 6.7% in women) than
EWGSOP criteria (20.8% overall, 25.5% in men and
16.2% in women) [11]. The combination of different
tools and adjustments also impacted prevalence rates;
specifically, the use of grip strength and ASM to define
sarcopenia yielded a prevalence of 11.7%, resembling
that observed in the SCOPE study though differing on
the gender predominance; likewise, the use of grip
strength, ASM and SPPB to define severe sarcopenia
yielded a prevalence of 2.2%. Other recent studies in
community-dwelling older adults have used EWGSOP2
criteria [34, 35] with varying prevalence rates of sarcope-
nia (20 and 3.4% respectively) and severe sarcopenia
(1.8% vs. 3.2%), though different assessment methods
were employed.
Sarcopenia has been reported to be common in
community-dwelling adults with CKD, with prevalence
rising markedly with declining kidney function [36]. Spe-
cifically, in adults with eGFR ≥90, eGFR 60–89 and
eGFR < 60ml/min/1.73m2 prevalence was 26.6, 38.9, and
60.1% respectively. It is worth noting that only muscle
mass with a less restringing cut-off was employed to de-
fine sarcopenia, which could account for the higher preva-
lence observed as compared with our results. Sarcopenia
has been found to be highly prevalent among patients with
CKD [37], and more prevalent among persons with lower
eGFR, with stage 4 CKD being independently associated
with an increased likelihood of sarcopenia. CKD has been
reported to be a major risk factor of sarcopenia in
community-dwelling older men [38], and that even stage
3 CKD had a more than threefold risk of skeletal muscle
mass (SMM) reduction.
In patients with stages 3–5 CKD on conservative ther-
apy, prevalence of sarcopenia was found to vary accord-
ing to the method used to assess muscle mass, with BIA
derived SMMI yielding lower estimates (5.9%) as op-
posed to the use of midarm muscle circumference
(9.8%) or subjective global assessment (9.4%) as surro-
gates of muscle mass [39]. Noteworthy, this study
assessed both muscle mass and strength components of
sarcopenia, which could account for the lower preva-
lence rates observed, far more similar to our results. An-
other study in a Korean population [40] found that
prevalence of sarcopenia was higher in patients even
with early stage kidney disease, with prevalence raising
as the stage of CKD increased from eGFR ≥90, to eGFR
60–89.9, and eGFR < 60ml/min/1.73m2 (2.6, 5.6 and
18.1% respectively in men, and 5.3, 7.1 and 12.6% re-
spectively in women), although a statistically significant
association between sarcopenia and stage of CKD was
found in men but not in women. In this regard, our
study found a higher prevalence among women across
virtually all CKD stages. Other studies in CKD patients
have observed variable prevalence rates of sarcopenia:
34.5% (stages 2-3a) and 65.5% (stages 3b-5) [14]; 37%
(stages 3–5) [41]; 14% (stages 3–5) greater in men (16%)
than in women (8%) and with a significant positive rela-
tionship between ASM and GFR [15]; and 12.5% (stages
3b-4 in men aged 60–74) or 55% (stages 3b-4 in men
aged > 75) [42].
Although several previous studies have evaluated the
relationship between muscle mass and/or muscle
strength and kidney function, to our knowledge this is
the first study to assess sarcopenia according to CKD
stages incorporating the revised EWGSOP2 criteria for
its definition. Furthermore, varying methods for estimating
Table 6 Prevalence of sarcopenia and sarcopenia categories according to ACR (mg/g) categories
Non-1sarcopenic (n = 1270) Sarcopenic (n = 150) p-value
ACR category No sarcopenia (n = 1114) Probable sarcopenia (n = 156) Confirmed sarcopenia (n = 65) Severe sarcopenia (n = 85)
< 30 (n = 1037) 941 (90.7%) 96 (9.3%) 0.008
842 (81.2%) 99 (9.5%) 46 (4.4%) 50 (4.8%)
30–300 (n = 288) 250 (86.8%) 38 (13.2%) 0.104
211 (73.3%) 39 (13.5%) 14 (4.9%) 24 (8.3%)
> 300 (n = 95) 79 (83.2%) 16 (16.8%) 0.039
61 (64.2%) 18 (18.9%) 5 (5.3%) 11 (11.6%)
ACR Albumin-to-creatinine ratio
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GFR have been employed, mainly the CKD-EPI and Modi-
fication of Diet in Renal Disease (MDRD) equations,
whereas few studies have employed measured GFR, e.g.,
through iohexol clearance method [15]. Sarcopenia is a
muscle disease closely related to ageing, and its prevalence
increases sharply within ageing populations, in which con-
cern exists about the accuracy of GFR estimating equations.
Performance of such equations has been compared against
equations specifically developed in older populations with
varying results [43]. In the SCOPE study it has been dem-
onstrated that CKD-EPI, BIS and FAS equations cannot be
considered interchangeable in a community-dwelling older
population, and that muscle mass may represent a major
source of discrepancy among equations [data not pub-
lished]. In the present study, the percentage of individuals
with sarcopenia in CKD stages 3–4 varied slightly accord-
ing to the equations employed: 13.9% for BIS, 14.2% for
CKD-EPI and 12.7% for FAS equation.
An increased risk of albuminuria, which is associated
with mortality, cardiovascular disease and CKD progres-
sion, has been reported in patients with sarcopenia and
vice versa, independently of CKD [17]. This association
has been found to be particularly strong in the older
adult population [44] and synergistic with obesity, and
also demonstrated in patients with type 2 diabetes [16].
Furthermore, sarcopenia has been associated with an in-
creased risk of progression of albuminuria in a retro-
spective study of diabetic patients [45], and with an
increased risk of incident albuminuria in a recent pro-
spective study in participants without CKD [46]. Com-
mon underlying mechanisms have been suggested to
account for this association, such as inflammation, insu-
lin resistance, endothelial dysfunction and renin-
angiotensin-aldosterone system activation. In the present
study a higher prevalence of sarcopenia is observed with
increasing ACR category: 9.3% in normoalbuminuric
participants, 13.2% in the microalbuminuric group and
16.8% in participants with macroalbuminuria (p = 0.019).
Some strengths of the present study are inherent to
the SCOPE study design, which included a remarkable
number of community-dwelling older adults from differ-
ent centers across Europe, following highly inclusive cri-
teria to ensure the enrolment of a representative sample
of real-world outpatients, within a wide range of kidney
function categories. Though previous studies have inves-
tigated sarcopenia prevalence, few studies have taken
CKD status into account, especially regarding CKD pa-
tients not on dialysis. Furthermore, the association of
higher rates of sarcopenia and kidney disease may de-
pend not only on CKD stage or degree of eGFR but also
on albuminuria status, with fewer studies assessing both
variables concomitantly or comparing different eGFR
equations. Moreover, as new revised definitions of sarco-
penia arise following the increasing knowledge of this
condition, the prevalence rates, the association with risk
factors or predisposing conditions, and even the associ-
ation with outcomes may differ from what was previ-
ously assumed. Thus, this is the first study to investigate
sarcopenia in patients not in ESRD incorporating the
newly recommended criteria by the EWGSOP2 consen-
sus for the definition of sarcopenia and its subtypes
through its three components (i.e.: muscle mass, muscle
strength and physical performance); and also assessing
not only different equations for the estimation of GFR,
but also albuminuria status as relevant measures related
to kidney function.
Some limitations deserve consideration. First, the
present study represents a cross-sectional analysis of
SCOPE study, and causality in the relationship between
sarcopenia and kidney function or albuminuria cannot
be established. Second, the exclusion of ESRD partici-
pants from the SCOPE study limits its applicability in
this group of patients. Third, although participants not
included in the analysis because of missing data on any
of the sarcopenia components did not seem to differ on
the majority of general characteristics from those who
completed sarcopenia assessment; a poorer clinical sta-
tus, poorer comorbidity profile or higher physical dis-
ability in those participants could have led to an
underestimation of sarcopenia prevalence in our study.
Fourth, the use of BIA for the estimation of ASM, al-
though endorsed by different consensuses because of its
affordability, availability and portability, may exhibit
some limitations as compared with DXA measurements
or with magnetic resonance imaging/computed tomog-
raphy (currently considered as gold standards for non-
invasive assessment of muscle mass); and hydration status
has to be taken into account as it may influence results, es-
pecially in CKD patients. Moreover, concern exists regard-
ing the use of height-adjusted ASM to correct for body
size, as it tends to underestimate the prevalence of sarcope-
nia and may not be suitable for all populations. As EWG-
SOP2 consensus makes no recommendation to adjust for
body size, a decision was made to employ non-adjusted
ASM as a measure of muscle mass. Finally the use of non-
creatinine based equations for the estimation of GFR, such
as eGFR based on cystatin C, might be more accurate for
the evaluation of sarcopenia in these patients; thus studies
comparing eGFR equations based on cystatin C or incorp-
orating measured GFR by iohexol clearance may be of para-
mount relevance. Creatinine is a metabolic product of
creatine and phosphocreatine arising from the muscle com-
partment, which is directly related to muscle mass. Thus,
muscle wasting may lead to an overestimation of eGFR in
sarcopenic patients, which should be taken into account
when evaluating such patients. Further research is needed
to investigate the underlying mechanisms of sarcopenia
among older adults with CKD and albuminuria.
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Conclusions
The main finding from our study is the relevant preva-
lence of sarcopenia observed among community-
dwelling European adults aged 75 years and older, using
the most recent diagnostic criteria for sarcopenia en-
dorsed by the EWGSOP2 consensus. Participants within
poorer eGFR categories, irrespective of the equation
used for its calculation, have a higher prevalence of sar-
copenia and are more often severely sarcopenic. There
are though some differences in prevalence according to
the eGFR formula used. Moreover, participants within
higher albuminuria categories are more often sarcopenic,
with higher rates of severe sarcopenia. Therefore,
prompt assessment of sarcopenia status may be war-
ranted in the usual care of older people with impaired
kidney function and/or albuminuria, which could allow
for its early detection and trigger proper interventions.
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